DEMANT.CO
Strong BuyPremium GrowerAI neutralDemant A/S · Healthcare · Denmark · $10.0B
DKK 319.20 +1.7% · close 5 Oct · scored 7 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Demant is one of the few global hearing aid makers, with brands such as Oticon, plus a hearing care clinic network. The industry is consolidated, and demand grows steadily with an ageing population, which gives it a durable position. Forward earnings estimates were cut by about 1% in the past four weeks, the business carries meaningful debt, and competitors keep launching new products. We see no macro catalyst that makes the risk-reward unusually attractive now.
ABOUT DEMANT A/S
Read
Demant A/S is a global hearing healthcare group engaged in the development, manufacture, and sale of hearing aids, cochlear implants, and diagnostic instruments, alongside operating a large hearing care retail chain. The company's competitive advantage stems from its integrated value chain, robust R&D, and portfolio of strong brands like Oticon, establishing it as a "Big 5" player in the industry.
FINANCIAL SUMMARY (DKK)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 19.7B | 21.6B | 22.4B | 23.0B | 5.2% | 24.8B | 26.3B | 28.0B | 10.5% |
| EPS (DKK) | 10.70 | 9.21 | 8.04 | 10.99 | 7.33 | -9.0% | 11.55 | 9.01 | 10.43 | 19.3% |
| Shares | — | 223.2M | 220.6M | 213.0M | 210.9M | -5.5% | 210.9M | — | — | — |
| Debt | — | 15.1B | 14.5B | 15.7B | 21.0B | 11.7% | 20.4B | — | — | — |
| Equity | — | 8.6B | 9.3B | 9.6B | 9.8B | 4.8% | — | — | — | — |
| Op CF | — | 2.6B | 4.5B | 4.1B | 3.9B | 13.7% | 3.9B | — | — | — |
| Inv CF | — | -3.3B | -1.8B | -1.8B | -7.0B | — | — | — | — | — |
| Fin CF | — | 934.0M | -2.4B | -2.2B | 3.3B | — | — | — | — | — |
Calmer than 65% of stocks we rank over the past year (33% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DEMANT.CO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DEMANT.CO | Demant A/S(you) | $10.0B | 82 | Strong Buy |
| GN.CO | GN Store Nord A/S | $2.4B | 74 | Buy |
| CHEMM.CO | ChemoMetec A/S | $1.4B | 87 | Strong Buy |
| AMBU-B.CO | Ambu A/S | $2.7B | 61 | Hold |
| CBHD.DE | Coloplast A/S | $14.3B | 73 | Buy |
| ALK-B.CO | ALK-Abelló A/S | $6.7B | 72 | Buy |
| GMAB.CO | Genmab A/S | $21.5B | 75 | Buy |
| HLUN-B.CO | H. Lundbeck A/S | $6.6B | 99 | Strong Buy |
| ZEAL.CO | Zealand Pharma A/S | $2.8B | 83 | Strong Buy |
| ASND | Ascendis Pharma A/S | $14.7B | 58 | Hold |
Peer medians: ROE 15.9% · P/E 14.6x · Gross margin 82.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.